VAS third-line eradication study

Efficacy of triple therapy with vonoprazan, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031190031

Enrollment

Registered

2019-05-27

Start date

2019-06-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection Helicobacter pylori

Interventions

sitafloxacin (100mg)+amoxicillin (750mg)+Vonoprazan (20mg) given on twice daily for 7days

Helicobacter pylori eradication therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: First line eradication(PPI+AMPC+CAM) and second line eradication(PPI+AMPC+MNZ) failure patients with H.pylori infection who want to take eradication treatment. Patients who give a written informed consent.

Exclusion criteria

Exclusion criteria: Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. Severe liver dysfunction, Severe renal dysfunction, Severe heart dysfunction. Patients who are disqualified for the study by physicians.

Design outcomes

Primary

Measure	Time frame
Eradication rate	—

Secondary

Measure	Time frame
Adverse event by questionnaire	—

Contacts

Public ContactSue Soichiro

Yokohama City University Hospital

ssue@yokohama-cu.ac.jp+81-45-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026